Champions Oncology, Inc. (CSBR) Financial Ratios
30 years of historical data (1996–2025) · Healthcare · Biotechnology
EV/EBITDA
↓
12.43
↓-72% vs avg
5yr avg: 44.71
30Y Low15.2·High82.8
P/FCF
↓
12.05
↓-65% vs avg
5yr avg: 34.18
30Y Low14.6·High133.5
P/B Ratio
↑
22.77
↑+22% vs avg
5yr avg: 18.61
30Y Low2.3·High140.8
ROE
↑
503.0%
↓+2756% vs avg
5yr avg: -18.9%
30Y Low-476%·High53%
Debt/EBITDA
↓
0.94
↓-69% vs avg
5yr avg: 3.00
30Y Low0.0·High4.9
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CSBR Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Champions Oncology, Inc. trades at 18.2x earnings, 92% below its 5-year average of 217.6x, sitting at the 0th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.2x, the stock trades at a discount of 18%. On a free-cash-flow basis, the stock trades at 12.1x P/FCF, 65% below the 5-year average of 34.2x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $84M | $102M | $66M | $67M | $109M | $156M | $91M | $128M | $48M | $29M | $34M |
| Enterprise Value | $81M | $98M | $71M | $65M | $109M | $161M | $87M | $125M | $47M | $26M | $31M |
| P/E Ratio → | 18.24 | 21.67 | — | — | 198.45 | 432.66 | — | 997.80 | — | — | — |
| P/S Ratio | 1.48 | 1.79 | 1.31 | 1.24 | 2.21 | 3.81 | 2.85 | 4.73 | 2.36 | 1.89 | 3.00 |
| P/B Ratio | 22.77 | 27.04 | — | 14.37 | 11.96 | 21.05 | 17.93 | 57.19 | — | 72.76 | 140.81 |
| P/FCF | 12.05 | 14.58 | — | 61.52 | 26.44 | — | 133.48 | 124.51 | — | — | — |
| P/OCF | 11.42 | 13.81 | — | 16.85 | 16.74 | — | 31.47 | 68.74 | — | — | — |
P/E links to full P/E history page with 30-year chart
CSBR EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Champions Oncology, Inc.'s enterprise value stands at 12.4x EBITDA, 72% below its 5-year average of 44.7x. The Healthcare sector median is 14.4x, placing the stock at a 13% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.73 | 1.41 | 1.21 | 2.22 | 3.93 | 2.70 | 4.61 | 2.32 | 1.68 | 2.77 |
| EV / EBITDA | 12.43 | 15.16 | — | — | 36.16 | 82.80 | — | 142.43 | — | — | — |
| EV / EBIT | 16.64 | 21.13 | — | — | 187.32 | 369.08 | — | 540.14 | — | — | — |
| EV / FCF | — | 14.05 | — | 60.12 | 26.55 | — | 126.84 | 121.37 | — | — | — |
CSBR Profitability
Margins and return-on-capital ratios measuring operating efficiency
Champions Oncology, Inc. earns an operating margin of 8.5%. Operating margins have expanded from -8.3% to 8.5% over the past 3 years, signaling improving operational efficiency. Return on equity of 503.0% is exceptionally high, though this is partly amplified by negative book value driven by aggressive share buybacks. ROIC of 242.2% represents excellent returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 47.3% | 47.3% | 41.4% | 45.2% | 51.9% | 47.7% | 47.1% | 47.3% | 47.9% | 37.0% | 22.3% |
| Operating Margin | 8.5% | 8.5% | -13.8% | -8.3% | 1.2% | 0.9% | -4.9% | 1.0% | -6.7% | -44.2% | -92.3% |
| Net Profit Margin | 8.3% | 8.3% | -14.5% | -9.9% | 1.1% | 0.9% | -6.5% | 0.5% | -7.3% | -44.7% | -93.4% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 503.0% | 503.0% | -532.5% | -77.7% | 6.6% | 5.8% | -57.1% | 11.6% | -787.2% | -2158.0% | -251.8% |
| ROA | 16.1% | 16.1% | -24.1% | -15.3% | 1.7% | 1.5% | -13.1% | 1.3% | -18.3% | -99.9% | -117.2% |
| ROIC | 242.2% | 242.2% | -172.3% | -52.7% | 4.2% | 4.3% | -214.3% | — | — | — | — |
| ROCE | 74.1% | 74.1% | -80.6% | -29.2% | 3.5% | 2.9% | -27.1% | 14.1% | -233.4% | -1315.7% | -236.6% |
CSBR Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Champions Oncology, Inc. carries a Debt/EBITDA ratio of 0.9x, which is very conservative (71% below the sector average of 3.3x). The company holds a net cash position — cash of $10M exceeds total debt of $6M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns. Interest coverage of 179.5x signals virtually no risk of debt distress — earnings comfortably cover interest obligations.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.62 | 1.62 | — | 1.85 | 1.04 | 1.29 | 0.74 | 0.01 | — | 0.16 | 0.35 |
| Debt / EBITDA | 0.94 | 0.94 | — | — | 3.13 | 4.93 | — | 0.02 | — | — | — |
| Net Debt / Equity | — | -0.98 | — | -0.33 | 0.05 | 0.66 | -0.89 | -1.44 | — | -8.08 | -10.51 |
| Net Debt / EBITDA | -0.57 | -0.57 | — | — | 0.15 | 2.52 | — | -3.68 | — | — | — |
| Debt / FCF | — | -0.53 | — | -1.40 | 0.11 | — | -6.63 | -3.13 | — | — | — |
| Interest Coverage | 179.48 | 179.48 | -247.18 | — | 25.29 | — | — | — | — | — | — |
Net cash position: cash ($10M) exceeds total debt ($6M)
CSBR Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.94x is below 1.0, meaning current liabilities exceed current assets.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.94 | 0.94 | 0.63 | 0.90 | 1.13 | 1.13 | 1.10 | 0.99 | 0.68 | 0.79 | 0.82 |
| Quick Ratio | 0.94 | 0.94 | 0.63 | 0.90 | 1.13 | 1.13 | 1.10 | 0.99 | 0.68 | 0.79 | 0.82 |
| Cash Ratio | 0.41 | 0.41 | 0.12 | 0.47 | 0.52 | 0.42 | 0.68 | 0.40 | 0.11 | 0.44 | 0.49 |
| Asset Turnover | — | 1.76 | 1.92 | 1.57 | 1.39 | 1.49 | 1.55 | 2.40 | 2.51 | 1.92 | 1.94 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 72.01 | 69.32 | 54.28 | 70.70 | 62.13 | 54.20 | 59.02 | 70.63 | 53.86 | 42.83 |
CSBR Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Champions Oncology, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 5.5% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 5.5% | 4.6% | — | — | 0.5% | 0.2% | — | 0.1% | — | — | — |
| FCF Yield | 8.3% | 6.9% | — | 1.6% | 3.8% | — | 0.7% | 0.8% | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 1.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 1.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $14M | $14M | $14M | $14M | $15M | $12M | $14M | $11M | $11M | $9M |
Peer Comparison
Compare CSBR with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CSBRYou | $84M | 18.2 | 12.4 | 12.1 | 47.3% | 8.5% | 503.0% | 242.2% | 0.9 |
 IMVT | $6B | -10.6 | — | — | — | — | -62.5% | — | — |
 CASI | $2M | -0.1 | — | — | 39.1% | -138.8% | -301.8% | -153.0% | — |
 TPVG | $234M | 4.7 | 9.0 | — | 83.5% | 77.9% | 14.1% | 7.2% | 6.2 |
 IDXX | $44B | 42.8 | 30.9 | 42.2 | 61.8% | 31.6% | 66.2% | 42.5% | 0.7 |
 NTRA | $28B | -127.8 | — | 252.3 | 64.8% | -13.4% | -14.3% | -36.1% | — |
 EXAS | $20B | -95.4 | — | 56.1 | 69.7% | -6.4% | -8.7% | -3.6% | — |
 AGEN | $135M | -1123.5 | — | — | 90.3% | -18.0% | — | — | — |
 CRL | $9B | -61.0 | 12.7 | 16.9 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
 IQV | $30B | 22.8 | 13.0 | 14.8 | 26.3% | 14.0% | 21.4% | 8.7% | 4.7 |
 MEDP | $12B | 27.7 | 21.1 | 17.8 | 30.1% | 21.1% | 70.2% | 154.9% | 0.4 |
| Healthcare Median | — | 22.2 | 14.4 | 18.6 | 64.0% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
See CSBR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CSBR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CSBR vs IMVT
Side-by-side business, growth, and profitability comparison vs Immunovant, Inc..
Start ComparisonCSBR — Frequently Asked Questions
Quick answers to the most common questions about buying CSBR stock.
What is Champions Oncology, Inc.'s P/E ratio?
Champions Oncology, Inc.'s current P/E ratio is 18.2x. The historical average is 110.1x.
What is Champions Oncology, Inc.'s EV/EBITDA?
Champions Oncology, Inc.'s current EV/EBITDA is 12.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 44.7x.
What is Champions Oncology, Inc.'s ROE?
Champions Oncology, Inc.'s return on equity (ROE) is 503.0%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -89.3%.
Is CSBR stock overvalued?
Based on historical data, Champions Oncology, Inc. is trading at a P/E of 18.2x. Compare with industry peers and growth rates for a complete picture.
What are Champions Oncology, Inc.'s profit margins?
Champions Oncology, Inc. has 47.3% gross margin and 8.5% operating margin.
How much debt does Champions Oncology, Inc. have?
Champions Oncology, Inc.'s Debt/EBITDA ratio is 0.9x, indicating low leverage. A ratio below 2x is generally considered financially healthy.